XML 26 R14.htm IDEA: XBRL DOCUMENT
v3.21.1

Fair Value Measurements | 3 Months Ended
--- | ---
Mar. 31, 2021
Fair Value Disclosures [Abstract] |
Fair Value Measurements |
9. | Fair Value Measurements
The carrying amounts of certain financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their respective fair values due to the short-term nature of such instruments. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached as of March 31, 2021 and December 31, 2020 for financial instruments measured at fair value on a recurring basis (in thousands):
|  |  |  |  |  | Fair Value Hierarchy Classification |
|  | Balance |  |  | Quoted Prices in Active Markets for Identical Assets (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
March 31, 2021 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash |  | $ | 236 |  |  | $ | 236 |  |  |  | — |  |  |  | — |
Restricted cash |  |  | 273 |  |  |  | 273 |  |  |  | — |  |  |  | — |
Money market funds |  |  | 91,775 |  |  |  | 91,775 |  |  |  | — |  |  |  | — |
Total assets |  | $ | 92,284 |  |  | $ | 92,284 |  |  |  | — |  |  |  | — |
Warrant liabilities |  | $ | 49,860 |  |  |  | — |  |  |  | — |  |  | $ | 49,860 |
Derivative liability |  |  | 2,618 |  |  |  | — |  |  |  | — |  |  |  | 2,618 |
Total liabilities |  | $ | 52,478 |  |  |  | — |  |  |  | — |  |  | $ | 52,478 |
December 31, 2020 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash |  | $ | 117 |  |  | $ | 117 |  |  |  | — |  |  |  | — |
Restricted cash |  |  | 273 |  |  |  | 273 |  |  |  | — |  |  |  | — |
Money market funds |  |  | 92,924 |  |  |  | 92,924 |  |  |  | — |  |  |  | — |
Total assets |  | $ | 93,314 |  |  | $ | 93,314 |  |  |  | — |  |  |  | — |
Warrant liabilities |  | $ | 51,156 |  |  |  | — |  |  |  | — |  |  | $ | 51,156 |
Derivative liabilities |  |  | 5,954 |  |  |  | — |  |  |  | — |  |  |  | 5,954 |
Total liabilities |  | $ | 57,110 |  |  |  | — |  |  |  | — |  |  | $ | 57,110 |
The Company measures cash equivalents at fair value on a recurring basis. The fair value of cash equivalents is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. Level 3 financial liabilities consist of the warrant liabilities for which there is no current market such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. The Company uses the Black-Scholes option valuation model to value the Level 3 warrant liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company’s stock price, contractual terms, maturity, risk free rates, as well as volatility. The unobservable input for all of the Level 3 warrant liabilities includes volatility. The historical volatility of the Company, using its closing common stock prices, is utilized to reflect future volatility over the expected term of the warrants. At March 31, 2021, the range and weighted average of the Level 3 volatilities utilized in the Black-Scholes model to fair value the warrant liabilities were 69.6% to 82.5% and 77.6%, respectively. Additionally, the expected term associated with the December 2019 Public Offering warrants is an unobservable unit given that the expiration of the warrants is the earlier of (i) such date that is six months after the Company publicly announces the approval from the U.S. Food and Drug Administration for ibrexafungerp for the treatment of vulvovaginal candidiasis and (ii) June 12, 2023. The Company utilized a probability assessment to estimate the likelihood of occurrence for the two potential expiration dates and allocated the probability of occurrence percentage to the fair values calculated based on the two potential expected terms. The weighted average expected term is 0.9 years as of March 31, 2021 for the December 2019 Public Offering warrants with a range of 0.66 to 2.2 years. The Company uses the binomial lattice valuation model to value the Level 3 derivative liabilit ies at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company’s stock price, contractual terms, dividend yield, risk-free rate, historical volatility, credit rating, market credit spread, and estimated effective yield. The unobservable inputs associated with the Level 3 derivative liabilit ies are adjusted equity volatility, market credit spread, and estimated yield. As of March 31, 2021, these inputs were 61.5%, 1,451 basis points, and 15.1%, respectively. The senior convertible notes are initially fair valued using the binomial lattice model and with the straight debt fair value calculated using the discounted cash flow method. The discount for lack of marketability, 7.1% as of March 31, 2021, is applied to the value of the March 2019 Notes. The residual difference represents the fair value of the embedded derivative liabilit ies and the fair value of the embedded derivative liabilit ies are reassessed using the binomial lattice valuation model on a quarterly basis. A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands):
|  |  | Warrant Liabilities |
Balance – December 31, 2020 |  |  | $ | 51,156 |
Gain adjustment to fair value |  |  |  | (1,296 | )
Balance – March 31, 2021 |  |  | $ | 49,860 |
|  |  | Derivative Liabilities |
Balance – December 31, 2020 |  |  | $ | 5,954 |
Adjustment for conversion of April 2020 Notes |  |  |  | (3,426 | )
Gain adjustment to fair value |  |  |  | 90 |
Balance – March 31, 2021 |  |  | $ | 2,618 |

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration